Cost-Effectiveness Analysis of Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in People With Type 2 Diabetes Treated With Non-Intensive Insulin Therapy in South Korea
Authors' conclusion
rt-CGM is likely to be cost-effective versus self-monitoring of blood glucose in the management of patients with type 2 diabetes receiving basal insulin regimens in South Korea.
Study context
- Population
- Simulated cohort of people with T2D receiving basal insulin regimens, South Koreasimulated cohort
- Exposure
- rtCGM vs SMBG
- Outcome
- Cost-effectiveness (lifetime horizon)
- Follow-up
- Remaining lifetime (up to 50 years)
Methodological detailsIQVIA Core Diabetes Model, South Korean payer perspective, simulated cohort based on Korea National Health and Nutrition Examination Survey, remaining lifetime horizon (up to 50 years), discount rate 4.5% per annum
- IQVIA Core Diabetes Model
- South Korean payer perspective
- Simulated cohort based on Korea National Health and Nutrition Examination Survey
- Remaining lifetime horizon (up to 50 years)
- Discount rate 4.5% per annum
Main finding
As reported in the abstract
Incremental quality-adjusted life expectancy
0.490 QALYs
Real-time continuous glucose monitoring (rt-CGM) vs SMBG · increase with rt-CGM
Incremental costs
13.3 million KRW
rt-CGM vs SMBG · increase with rt-CGM
Incremental cost-utility ratio
27.1 million KRW per QALY
Between rt-CGM and SMBG · base case; below willingness-to-pay threshold of KRW 47 million
Observational data: associations, not effects.
Original publication
Cost-Effectiveness Analysis of Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in People With Type 2 Diabetes Treated With Non-Intensive Insulin Therapy in South Korea. J Diabetes Sci Technol. Published 21 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →